- March 30, 2020
1:00 PM - 5:00 PM ET
Due to extenuating circumstances, this meeting is being postponed until further notice.
On March 30th, 2020, FDA is hosting a public meeting on Patient-Focused Drug Development for Vitiligo. FDA is interested in hearing patients’ perspectives on the impact of vitiligo on daily life and patient views on treatment approaches.
This website will be updated as meeting materials are developed.
March 30, 2020
1:00 p.m. - 5:00 p.m. (registration will begin at 12:00 p.m.)
FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Great Room
Silver Spring, MD 20903
(Information about arrival to FDA’s White Oak campus)
To register for this meeting, visit: Public Meeting on Patient-Focused Drug Development for Vitiligo
We recommend early registration for the meeting.
In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket.
- The docket closes on June 1, 2020. FDA is interested in responses to the questions listed in the Federal Register Notice.
- Public Docket Information